Tech giant Oracle (ORCL) recently revealed its latest AI agents that are designed to support supply-chain workers in various roles, from

Oracle Corporation (NYSE:ORCL) lost around $70 billion in market share after the stock price was down 14%. The firm has been making heavy investments in developing data centers in a bid to compete with big players like Amazon, Microsoft and Google.

Oracle looks like a big winner from the new Stargate Project. The tech giant began working more closely with OpenAI last summer. Oracle is outgrowing leaders like Amazon in cloud-infrastructure revenue.

Financial writer analyzes ORCL's performance in the generative AI boom, warns of inflated valuations, and recommends taking profits.

Oppenheimer analysts view the news that DeepSeek, an open-source Chinese large language model, is outperforming OpenAI’s models at a fraction

The company is one of the app’s leading server providers, managing the data centers where billions of 40-second videos are stored.

Below is Validea's guru fundamental report for ORACLE CORP (ORCL). Of the 22 guru strategies we follow, ORCL rates highest using our Multi-Factor Investor model based on the published strategy of ...

Below is Validea's guru fundamental report for ORACLE CORP (ORCL). Of the 22 guru strategies we follow, ORCL rates highest using our Multi-Factor Investor model based on the published strategy of ...

Oracle ( ORCL ), fresh off of announcing its part in the massive Stargate Project alongside OpenAI and SoftBank, debuted its latest AI agents aimed at manufacturers during its CloudWorld event in Austin Thursday. Scott Bessent confirmed as Treasury secretary, giving him a key role in extending Trump's tax cuts

Shares of Oracle (NYSE: ORCL) are sinking Monday. The firm's stock had lost 14.2% as of 2:45 p.m. ET, but was down as much as 15.5% earlier in the day. The surge comes as the S&P 500 and Nasdaq Composite lost 1.8% and 3.2%, respectively.

Overall, the analysts view DeepSeek’s emergence as a “negative for AI training and positive for inferencing infrastructure”, highlighting potential beneficiaries such as NET, DOCN, and EQIX.

This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy point.